Haemocomplettan P (Human Fibrinogen)

Haemocomplettan P is indicated for the replacement of fibrinogen in several clinical situations where low plasma fibrinogen contributes to bleeding risk.

• Congenital fibrinogen deficiency, including afibrinogenemia and hypofibrinogenemia.
• Acquired hypofibrinogenemia associated with liver disease, massive transfusion, or disseminated intravascular coagulation.
• Massive hemorrhage where rapid fibrinogen replacement is required.
• Surgical or trauma‑related bleeding when fibrinogen levels are below therapeutic thresholds.
• Situations where conventional blood components are unavailable or contraindicated.

Side effects of Haemocomplettan P may vary in frequency and severity. Monitoring for any adverse reaction after infusion is recommended.

Common

• Mild fever or chills.
• Headache.
• Nausea or vomiting.
• Transient hypotension.
• Local infusion site reactions such as erythema or pain.

Serious

• Allergic or anaphylactic reactions.
• Thromboembolic events (e.g., deep vein thrombosis, pulmonary embolism).
• Disseminated intravascular coagulation.
• Severe hypotension or shock.
• Hemolysis or renal impairment.

Before using Haemocomplettan P, clinicians should assess patient history and current clinical status to mitigate risks.

• Verify baseline fibrinogen level and avoid over‑correction.
• Use caution in patients with a history of thrombosis or hypercoagulable states.
• Monitor for signs of allergic reaction during and after infusion.
• Adjust dose in patients with renal or hepatic impairment as needed.
• Ensure compatibility with other intravenous solutions.
• Maintain aseptic technique to prevent contamination.
• Document infusion details and patient response for pharmacovigilance.

Haemocomplettan P may interact with other agents that affect coagulation or immune response.

Avoid

• Concurrent use of pro‑coagulant agents (e.g., activated factor VII) without careful monitoring.
• High‑dose anticoagulants that could mask fibrinogen deficiency.

Use with caution

• Other plasma‑derived products (e.g., cryoprecipitate, fresh frozen plasma).
• Immunomodulatory drugs that may alter allergic response risk.
• Medications that affect renal or hepatic function, requiring dose adjustments.
• Blood pressure‑lowering agents if hypotension occurs during infusion.